ADMA Biologics Receives a Split FDA Decision on BIVIGAM Gallery ADMA Biologics Receives a Split FDA Decision on BIVIGAM Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents ADMA Biologics Receives a Split FDA Decision on BIVIGAM By Bill Langbein|2018-12-20T15:03:58-05:00December 20th, 2018|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents|Tags: ADMA, BIVIGAM, PDUFA| ADMA Biologics (NASDAQ:ADMA), a company specializing in the manufacturing and development [...] Read More 0